Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Bacopa Monnieri | Sabroxy (Oroxylum indicum) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands) | — |
| Timing | With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects. | — |
| Cycle Duration | Ongoing; benefits accumulate over months. No strict cycling required. | — |
| Evidence Level | strong_human | Emerging |
Active triterpenoid saponins (bacosides A and B) provide multifaceted neuroprotection: inhibition of acetylcholinesterase (AChE) and activation of choline acetyltransferase (ChAT) to enhance cholinergic neurotransmission; upregulation of tryptophan hydroxylase and serotonin transporter expression to modulate serotonergic tone; antioxidant neuroprotection via induction of superoxide dismutase and glutathione peroxidase; and reduction of beta-amyloid aggregation. Additionally enhances GABA signaling through GABA-A receptor subunit upregulation and glutamate decarboxylase activation.
300-450 mg/day of standardized extract (24-55% bacosides, typically Bacognize or Synapsa brands)
With a fat-containing meal to improve absorption of fat-soluble bacosides. Morning or evening — some users report mild sedation. Minimum 8-12 weeks for full cognitive effects.
Ongoing; benefits accumulate over months. No strict cycling required.
Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →